Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3-year versus 5-year ovarian function suppression with endocrine therapy in premenopausal hormone receptor-positive early breast cancer
ChiCTR2100049809Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gonadotropin-releasing hormone agonist and tamoxifen in breast cancer (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: disease-free survival. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
gonadotropin-releasing hormone agonisttamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100049809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049809.